StemEx lowers mortality rate in patients with blood cancers

02/5/2013 | Globes (Israel)

Gamida Cell said a late-stage clinical trial found its allogeneic stem cell treatment, StemEx, can reduce mortality rates among leukemia and lymphoma patients. The death rate 100 days after StemEx treatment was 15.8%, compared with 24.5% for those treated with two double cord umbilical blood transplants.

View Full Article in:

Globes (Israel)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
In house Compliance Officer
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC